Notice for encorafenib (Pierre Fabre Australia Pty Ltd)
Active ingredients
encorafenib
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Dosage form(s)
Hard capsule
Indication
For the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation as detected by a validated test, who have received prior systemic therapy
Therapeutic area
Oncology